Patents by Inventor Melanie Rieger

Melanie Rieger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating asthma with polypeptides targeting IL-13 and TSLP
    Patent number: 11840566
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: December 12, 2023
    Assignees: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20220177566
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 9, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20220177565
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 9, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20220177564
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 9, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND OX40L
    Publication number: 20220153854
    Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISV binds to OX40L and at least two ISVDs bind to IL-13. The present disclosure also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: September 24, 2021
    Publication date: May 19, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Klaus Erb, Eric Lorent, John Park, Robert Resnick, Melanie Rieger, Bernd Weigle
  • Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
    Patent number: 11208476
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: December 28, 2021
    Assignees: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20210214431
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: March 22, 2021
    Publication date: July 15, 2021
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernhard Weigle, Klaus Erb
  • POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
    Publication number: 20210188965
    Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: December 9, 2020
    Publication date: June 24, 2021
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb